FFEC
PVLA

First Financial Equity Corporation’s Palvella Therapeutics PVLA Stock Holding History

First Financial Equity Corporation’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$28K Buy
+125
New +$22.1K ﹤0.01% 442

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Financial Equity Corporation's PVLA Position: Q1 2017 in Review

First Financial Equity Corporation opened a new position in Palvella Therapeutics (PVLA) in Q1 2017: 125 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #442 among its holdings.

27 funds tracked by Wall St. Rank hold PVLA as of Q1 2017.

  • First Financial Equity Corporation held 125 shares of Palvella Therapeutics worth $28K as of Q1 2017.
  • Palvella Therapeutics was a new First Financial Equity Corporation position in Q1 2017.
  • Palvella Therapeutics made up ﹤0.01% of First Financial Equity Corporation's portfolio in Q1 2017, its #442 holding.
  • 27 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2017.

Based on First Financial Equity Corporation's 13F filing for Q1 2017, filed 16 May 2017.